Fortis Healthcare Share News - Latest Updates, Live News & More

Latest news about Fortis Healthcare

Fortis Healthcare Schedules Board Meeting and Conference Call for Q3FY26 Results 3 hrs ago Today

Fortis Healthcare Limited has announced comprehensive arrangements for Q3FY26 financial results presentation, including a board meeting on February 13, 2026, and a subsequent conference call on February 16, 2026, at 11:00 AM IST with detailed dial-in information for domestic and international participants.

Fortis Healthcare Completes Postal Ballot for Director Appointment with Overwhelming Shareholder Approval Jan 23, 2026

Delhi High Court Issues Criminal Complaint Over Forged Term Sheet in Fortis Healthcare-Walmark Dispute Jan 22, 2026

NCLT Approves Merger of Fortis Healthcare Subsidiaries with Fortis Hospitals Limited Jan 16, 2026

Fortis Healthcare Records ₹25.38 Crore NSE Block Trade at ₹912.20 Per Share Jan 14, 2026

More news about Fortis Healthcare

08Jan 26

Fortis Healthcare Announces Aggressive Expansion Plan with Over 3,200 Beds by 2030

Fortis Healthcare has revealed plans for substantial expansion with over 3,200 new beds by 2030, supported by strategic acquisitions in Bangalore and Punjab. The company has completed the IHH Open Offer closure and is experiencing growth in medical tourism alongside improved ARPOB and occupancy rates, while strengthening its diagnostic B2C segment focus.

07Jan 26

Fortis Healthcare Releases Comprehensive Investor Presentation for US Roadshow

Fortis Healthcare has submitted detailed investor presentation materials for its January 12-15, 2026 US roadshow and JP Morgan Healthcare Conference. The presentation showcases strong consolidated business performance with 10.90% revenue CAGR from FY20-25, extensive network of 34 healthcare facilities with 5,900 operational beds, and ambitious expansion plans to add 3,200+ beds by FY30 representing 10.70% capacity growth CAGR.

06Jan 26

Fortis Healthcare Subsidiary Receives ₹597.93 Crore GST Demand Order from Tamil Nadu

Fortis Healthcare's subsidiary faces a significant GST demand of ₹597.93 crores from Tamil Nadu tax authorities for denied healthcare service exemptions, though the company plans to appeal and expects no material impact. Despite this regulatory challenge, Fortis maintains its strong market position with CRISIL reaffirming its AA+ credit rating based on robust financial performance including 17% revenue growth and improved margins.

30Dec 25

Fortis Healthcare Receives GST Orders Worth ₹2,139.61 Crores from Tamil Nadu Authorities

Fortis Healthcare Limited disclosed receipt of GST orders from Tamil Nadu authorities totaling ₹2,139.61 crores across FY 2020-21 to 2022-23. The confirmed demands include ₹478.08 crores for FY 2020-21, ₹850.00 crores for FY 2021-22, and ₹811.53 crores for FY 2022-23, all inclusive of interest and penalties. The orders were received between December 29-30, 2025, with the company making the mandatory disclosure under SEBI Regulation 30.

23Dec 25

Fortis Healthcare Wins Legal Case Against Third Party in Delhi High Court

Fortis Healthcare has secured a favorable ruling from the Delhi High Court in a civil suit against a third party. The court granted a permanent injunction against the third party's actions and upheld Fortis Healthcare's challenge to their locus. The case originated from arbitration proceedings initiated by a party claiming to be an assignee of a third party, which Fortis Healthcare contested. The company has confirmed that this legal settlement will have no financial impact, with no compensation or penalty paid.

22Dec 25

Fortis Healthcare Completes ₹130.47 Crore Interest Payment to Debenture Holders

Fortis Healthcare Limited successfully completed annual interest payments totaling ₹130.47 crores to debenture holders on December 22, 2025, covering three debenture series with a combined principal amount of ₹1,550 crores. The payments were made to major financial institutions including DBS Bank Limited, The Hongkong And Shanghai Banking Corporation Limited, and Citicorp Investment Bank (Singapore) with Mizuho Bank Limited, demonstrating the company's adherence to regulatory compliance under SEBI guidelines.

20Dec 25

Fortis Healthcare Subsidiary IHL Finalizes Acquisition of TMI Healthcare and Hospital Properties

Fortis Healthcare's subsidiary IHL has finalized agreements to acquire TMI Healthcare, including its healthcare operations and hospital properties. This strategic move aims to strengthen Fortis Healthcare's market position and expand its healthcare infrastructure.

20Dec 25

Fortis Healthcare Plans ₹840 Cr Investment for 300-Bed Expansion in Bengaluru

Fortis Healthcare has unveiled a comprehensive ₹840 crore investment plan for Bengaluru, combining the ₹430 crore acquisition of the 125-bedded PeopleTree Hospital Yeshwanthpur with ₹410 crore in planned infrastructure development over three years. The strategic initiative will expand the facility to 300 beds and includes an adjacent 0.80-acre land parcel, supporting Fortis's cluster-focused growth strategy in a market where it aims to scale from 900 to 1,500 beds across seven facilities.

19Dec 25

Fortis Healthcare Issues Postal Ballot Notice for Director Appointment Approval

Fortis Healthcare has issued a comprehensive postal ballot notice seeking shareholder approval for the appointment of Mr. Mohd Shahazwan Bin Mohd Harris as Non-Independent Non-Executive Director. The 54-year-old nominee brings over 25 years of experience in investments and corporate strategy, currently serving as Advisor at UEM Group. The e-voting process runs from December 24, 2025 to January 22, 2026, with multiple access methods available through KFintech platform.

19Dec 25

Fortis Healthcare Executes ₹37.11 Crore NSE Block Trade at ₹885.10 Per Share

Fortis Healthcare conducted a significant block trade on the National Stock Exchange (NSE), involving 419,265 shares at ₹885.10 per share. The total transaction value amounted to ₹37.11 crores, indicating strong institutional interest in the healthcare company's stock. This large-volume trade was executed outside regular market hours, demonstrating the price discovery mechanism for substantial transactions in Fortis Healthcare's shares.

04Dec 25

Fortis Healthcare Receives BSE Approval for Debenture Term Modifications

Fortis Healthcare has successfully obtained final regulatory approval from BSE Limited for modifications to its non-convertible debentures, with the approval granted on December 19, 2025. The company disclosed this development under SEBI regulations, marking the completion of a debt restructuring process that demonstrates its commitment to optimizing financial structure and maintaining regulatory compliance.

18Nov 25

Fortis Healthcare Reports 17.3% Revenue Growth in Q2 FY26, Driven by Strong Hospital Performance

Fortis Healthcare's Q2 FY26 consolidated revenue increased by 17.3% to INR2,331.00 crores. Hospital segment revenue grew 19.3% to INR1,974.00 crores, while diagnostics revenue rose 7.1% to INR357.00 crores. Consolidated operating EBITDA surged 28% to INR556.00 crores, with EBITDA margin expanding to 23.9%. Profit after tax before exceptional items increased by 20.7% to INR305.00 crores. Hospital occupancy improved to 71%, with a 13% increase in occupied beds. The company expanded through lease agreements, acquisitions, and operational partnerships, adding 550 operational beds in H1 FY26.

17Nov 25

Fortis Healthcare Reports Robust Q2 FY26 Performance with 17.3% Revenue Growth and Margin Expansion

Fortis Healthcare reported consolidated revenue of INR 2,331.00 crores in Q2 FY26, a 17.3% year-on-year increase. Hospital business revenue grew 19.3% to INR 1,974.00 crores, while diagnostics business revenue increased 7.1% to INR 357.00 crores. Operating EBITDA rose 28% to INR 556.00 crores, with margins expanding to 23.9%. Hospital occupancy improved to 71%, and ARPOB increased by 5.8%. The company expanded its network through new agreements and acquisitions, adding 550 operational beds in H1 FY26.

11Nov 25

IHH Healthcare Concludes Open Offers for Fortis Healthcare and Fortis Malar with Minimal Shareholder Participation

IHH Healthcare Berhad has completed mandatory open offers for Fortis Healthcare Limited and Fortis Malar Hospitals Limited. The offers saw low shareholder participation, with only 1,778 shares (0.00%) tendered for Fortis Healthcare and 4,523 shares (0.02%) for Fortis Malar Hospitals. Post-offer, IHH's indirect shareholding stands at 31.17% in Fortis Healthcare and 62.73% in Fortis Malar Hospitals. The transaction included a preferential allotment of 235,294,117 new Fortis shares to IHH's subsidiary, Northern TK Venture Pte Ltd.

16Oct 25

Fortis Healthcare Announces Open Offer Tendering Period for Fortis and Malar Hospitals

IHH Healthcare Berhad has initiated open offers for Fortis Healthcare Limited and Fortis Malar Hospitals Limited, running from October 20 to November 4, 2025. The Fortis Healthcare offer aims to acquire 26.10% of expanded voting share capital, while the Fortis Malar offer targets 26.11%. Northern TK Venture Pte Ltd, an IHH subsidiary, will subscribe to 235,294,117 new Fortis shares. Separately, Fortis Healthcare has begun a postal ballot process for appointing Dr. Keith Hsiu Chin Lim as a Non-Independent & Non-Executive Director, with voting to conclude by November 15, 2025.

16Oct 25

Fortis Healthcare Seeks Shareholder Approval for Dr. Keith Hsiu Chin Lim's Board Appointment

Fortis Healthcare has initiated a postal ballot to ratify Dr. Keith Hsiu Chin Lim's appointment as a Non-Independent & Non-Executive Director. Dr. Lim, nominated by Northern TK Venture Pte. Limited, was initially appointed as an Additional Director on September 09, 2025. Shareholders can vote from October 17 to November 15, 2025, with results expected by November 18. Dr. Lim, currently Group Chief Medical Officer at IHH Healthcare, brings over 20 years of experience as a radiation oncologist and has held key positions in healthcare management and policy.

06Oct 25

Fortis Healthcare Shares Surge as IHH Healthcare Gets SEBI Nod for Long-Awaited Open Offer

Fortis Healthcare shares rose 3% after SEBI approved Malaysia-based IHH Healthcare Berhad's open offer to acquire an additional 26% stake. This approval comes after a long delay since 2018 due to legal complications. The original offer price was ₹170 per share, but Fortis' current trading price is around ₹980, a 4.7x increase. At current prices, the open offer could amount to approximately ₹19,308 crore. Fortis stock has shown strong momentum, up 2.80% on the latest trading day and 7% over the past month.

03Oct 25

SEBI Greenlights IHH Healthcare's Open Offer for Fortis Healthcare and Fortis Malar Hospitals

IHH Healthcare Berhad received SEBI approval for open offers to acquire stakes in Fortis Healthcare and Fortis Malar Hospitals. The transaction includes a preferential allotment of 235,294,117 new Fortis shares to IHH's subsidiary, and mandatory open offers for up to 26.10% of Fortis Healthcare and 26.11% of Fortis Malar Hospitals. This approval ends a regulatory delay since 2018, potentially reshaping India's private healthcare sector.

01Oct 25

Fortis Healthcare Inks O&M Agreement for Gleneagles BGS Hospital, Effective October 2025

Fortis Healthcare Limited has signed an Operations and Maintenance (O&M) agreement for Gleneagles BGS Hospital in Karnataka, effective from October 1, 2025. The agreement, disclosed through a regulatory filing, follows an earlier intimation made on July 23, 2025. The company confirmed that all necessary acceptances and No Objection Certificates from relevant third parties have been obtained, allowing the agreement to proceed as planned.

09Sept 25

Fortis Healthcare Announces Board Changes: Dr. Keith Lim Joins, Tomo Nagahiro Departs

Fortis Healthcare Limited has appointed Dr. Keith Hsiu Chin Lim as an Additional Director (Non-Executive & Non-Independent) effective September 09, 2025. Simultaneously, Tomo Nagahiro has resigned from his position as Non-Executive & Non-Independent Director. Dr. Lim, currently Group Chief Medical Officer at IHH Healthcare, brings over 20 years of experience as a radiation oncologist. He serves as a nominee director of Northern TK Venture Pte. Ltd., along with several other board members.

05Sept 25

Fortis Healthcare Inks Hospital Land and Equipment Lease Deal in Greater Noida

Fortis Healthcare has entered into a strategic agreement for hospital land and equipment lease in Greater Noida, expanding its presence in the National Capital Region (NCR). The agreement involves Fortis Healthcare, Uttar Pradesh State Industrial Development Authority (UPSIDA), and R.R. Lifesciences Pvt Ltd. This move allows Fortis to establish a presence in the growing Greater Noida area, potentially tapping into a new patient base. The company is adopting an asset-light approach by leasing rather than purchasing, which could be more cost-effective in the short term.

02Sept 25

Fortis Healthcare Expands Delhi-NCR Footprint with 200-Bed Greater Noida Hospital

Fortis Healthcare's subsidiary, International Hospital Limited, has leased a 200-bed multi-specialty hospital in Greater Noida for 15 years. This expansion increases Fortis' bed capacity in Delhi-NCR to about 2,000. The facility has potential for 50 additional beds. IHL will pay a monthly rent of Rs. 2.40 crore plus GST, with a Rs. 60 crore refundable security deposit. The strategically located hospital is well-connected and near the upcoming Jewar International Airport. Fortis has also completed a corporate restructuring process involving its subsidiaries.

06Aug 25

Fortis Healthcare Reports Strong Q1 FY26 Results, Unveils Ambitious Expansion Plans

Fortis Healthcare reported robust Q1 FY26 results with 16.60% revenue growth to INR 2,167.00 crore and 56.80% PAT growth to INR 260.00 crore. The hospital business saw 18.60% revenue growth, while diagnostics arm Agilus grew by 7.40%. Fortis announced expansion plans including an O&M agreement with Gleneagles India for managing 700 beds, acquisition of Shrimann Superspecialty Hospital adding 228 beds, and aims to add over 1,000 new beds. The company is focusing on high-profit specialties and increasing international patient revenue.

06Aug 25

Fortis Healthcare Reports Robust Q1 FY26 Results with 16.6% Revenue Growth

Fortis Healthcare announced robust financial results for Q1 FY26. Consolidated revenues increased by 16.6% to INR 2,167.00 crore. Operating EBITDA surged 43.2% to INR 491.00 crore, with margin expanding to 22.6%. PAT grew 56.8% to INR 260.00 crore. Hospital business revenues rose 18.6% to INR 1,838.00 crore, while diagnostics arm Agilus saw 7.4% revenue growth. The company entered an O&M agreement with Gleneagles India and acquired Shrimann Superspecialty Hospital in Jalandhar.

31Jul 25

Fortis Healthcare Secures NCLT Approval for Subsidiary Merger Scheme

Fortis Healthcare has secured final NCLT approvals from New Delhi and Chandigarh for its composite merger scheme involving four wholly-owned subsidiaries. The restructuring merges Fortis Emergency Services, Fortis Cancer Care, Fortis Health Management (East), and Birdie & Birdie Realtors into Fortis Hospitals Limited, with an appointed date of April 1, 2022. The scheme aims to rationalize operations and reduce administrative overhead without affecting the listed entity's shareholding pattern.

24Jul 25

Fortis Healthcare Subsidiary Completes Acquisition of Shrimann Superspecialty Hospital

Fortis Healthcare's subsidiary, Fortis Hospotel Limited (FHTL), has completed the acquisition of Shrimann Superspecialty Hospital's entire business operations, including hospital land and adjacent property. The transaction was finalized on July 24, 2025, at 09:14 PM IST. This acquisition follows earlier announcements made to stock exchanges in February, March, and May 2025. Fortis Healthcare has informed the National Stock Exchange of India Ltd. and BSE Limited about the transaction completion, in compliance with SEBI regulations.

24Jul 25

Fortis Healthcare Shares Soar to Record High on Landmark Gleneagles Hospital Management Deal

Fortis Healthcare's shares reached a new all-time high of Rs 839.90 following the announcement of a strategic collaboration with IHH Healthcare Berhad. The company signed an operation and maintenance services agreement to manage five out of six hospitals under the Gleneagles India network. Fortis will receive a monthly service fee of 3% of the net revenue of the hospitals. The deal aims to strengthen IHH's business in India and unlock operational and financial synergies. The market responded positively, with Fortis shares rising 1.97% and trading volume 3.8 times the 30-day average. Analysts maintain a largely positive outlook on the stock.

21Jul 25

Agilus Secures 'SRL' Trademarks for ₹8 Crore in Delhi High Court Auction

Agilus Diagnostics Limited, a subsidiary of Fortis Healthcare, has successfully purchased the 'SRL' trademarks for ₹8.00 crore through a court-sanctioned auction conducted by the Delhi High Court. The trademarks were previously owned by RHC Holding Private Limited and were made available for auction to satisfy a decree in favor of Daiichi Sankyo Company Limited. The acquisition follows a complex legal process involving multiple parties and is part of a larger dispute stemming from a 2016 Singapore tribunal arbitral award. Fortis Healthcare stated that there are no additional financial implications due to compensation or penalties arising from this sale.

30Jun 25

Fortis Healthcare Unveils Ambitious Expansion Plans, Targets 14-15% Revenue Growth

Fortis Healthcare plans to add 900 beds in the coming year as part of its expansion strategy. The company targets 14-15% revenue growth for FY26. Its hospital segment showed 14% year-over-year revenue growth in Q4 FY25 with improved occupancy rates and increased ARPOB. The diagnostics segment has been rebranded as 'Agilus' with expectations of stronger performance from FY26. Analysts maintain an 'Outperform' rating on Fortis Healthcare's stock.

21May 25

Fortis Healthcare Reports Q4 Revenue Growth, Targets Higher Margins

Fortis Healthcare's Q4 results show revenue growth of 12.40% to ₹2,007.00 crore, but a 7.40% decrease in net profit to ₹188.00 crore. The company reported an exceptional loss of ₹53.57 crore. Despite challenges, PBT increased by 8.20%. Fortis announced a final dividend of ₹1.00 per share. Quarterly performance shows significant improvements in EBITDA and net profit. The company aims to improve margins by FY26 through maintaining high occupancy, increasing complex procedures, and adding 800 new beds this year.

20May 25

Fortis Healthcare Q4: Net Profit Drops 7%, Revenue Surges, Dividend Recommended

Fortis Healthcare's Q4 results show a 12.4% YoY revenue increase to ₹2,007.20 crore and improved EBITDA of ₹440.00 crore. However, net profit decreased by 7.44% to ₹188.02 crore due to exceptional impairment losses. The board recommended a final dividend of ₹1.00 per equity share.

06May 25

Fortis Healthcare's Tax Demand Nullified: A Win for Subsidiary Fortis Hospitals

Fortis Healthcare Limited announced that its subsidiary, Fortis Hospitals Limited, received a favorable rectification order under the Income Tax Act. The order nullifies a previous tax demand of Rs. 89.53 crores for the Assessment Year 2022-23. The rectification, issued on May 05, 2025, corrects mistakes in the earlier assessment order. Fortis Healthcare stated this development would not impact its financial or operational activities in quantifiable monetary terms.

06May 25

Fortis Healthcare Subsidiary's ₹89.53 Crore Tax Demand Nullified

Fortis Healthcare Limited announced that its subsidiary, Fortis Hospitals Limited, received a rectification order from the Income Tax Department. The order reduces a previous tax demand of ₹89.53 crore for the assessment year 2022-23 to nil. The rectification, issued on May 5, 2025, corrects mistakes in the earlier assessment order. Fortis Healthcare stated that this development has no quantifiable impact on the company's financial or operational activities.

05May 25

Fortis Healthcare Receives Favorable Tax Rectification Order, Eliminating ₹89.53 Crore Demand

Fortis Healthcare's subsidiary, Fortis Hospitals Limited, has received a favorable rectification order under the Income Tax Act. The initial tax demand of ₹89.53 crore for the Assessment Year 2022-23 has been reduced to nil. This rectification, issued on May 5, 2025, corrects errors in the original assessment order. Fortis Healthcare states this development will not impact its financial or operational activities in quantifiable monetary terms.

03Apr 25

Fortis Healthcare Subsidiary Faces ₹76.19 Crore Tax Demand, Plans Appeal

International Hospital Limited (IHL), a subsidiary of Fortis Healthcare, has received an income tax demand of ₹76.19 crore for the Assessment Year 2019-20. The demand stems from disallowed interest expenses. IHL is considering appealing the order. Fortis Healthcare states this will not materially impact IHL's financials or operations.

03Apr 25

Fortis Healthcare Secures Ownership of 'Fortis' Brand in Landmark Delhi High Court Ruling

The Delhi High Court has confirmed the sale of 'Fortis' trademarks to Fortis Healthcare Limited for ₹200.00 crore, ending a complex legal dispute. The ruling rejects objections to the valuation and auction process, grants Fortis Healthcare full ownership rights, and allows for trademark registration transfer. The court has scheduled the execution of the sale deed for April 16, 2025.

02Apr 25

Fortis Healthcare Secures 'Fortis' Trademark for Rs 200 Crore in Delhi High Court Ruling

Fortis Healthcare Limited has won a significant legal battle, obtaining full ownership of its brand name and associated trademarks. The Delhi High Court confirmed the sale of the 'Fortis' marks to the healthcare provider for Rs 200.00 crore. This decision follows a Supreme Court judgment from September 2022 that made these trademarks available for satisfying a decree in favor of Daiichi Sankyo Company Limited. The acquisition allows Fortis Healthcare to solidify its brand identity, potentially enhancing its market value and investor confidence.

24Mar 25

Fortis Healthcare Faces Legal Hurdle in Shrimann Hospital Sale

Fortis Healthcare faces a legal setback as an ex-parte injunction order stops the planned sale of Shrimann Hospital. Shrimann Hospital is seeking an amicable settlement to vacate the order. This legal obstacle could impact Fortis's strategic plans, financial projections, and investor sentiment. The healthcare sector is closely watching the situation's resolution and its potential effects on Fortis's performance and growth strategy.

21Mar 25

Fortis Healthcare Faces Legal Hurdle in Shrimann Hospital Acquisition

Fortis Healthcare Limited's planned acquisition of Shrimann Hospital in Jalandhar has been temporarily halted by an ex-parte injunction order issued on March 20, 2025. The order stems from a petition filed by Cancer Treatment Services Hyderabad Private Limited against Shrimann Hospital regarding alleged dues. Fortis Healthcare, not a party to the litigation, reports that Shrimann Hospital is seeking an amicable settlement and vacation of the injunction. This legal obstacle comes despite recent shareholder approval for the acquisition and related financial arrangements.

06Mar 25

Fortis Healthcare Sees Significant Block Trade on NSE

A significant block trade of 561,829 Fortis Healthcare shares occurred on the National Stock Exchange at Rs. 665.55 per share, totaling Rs. 37.39 crores. This large transaction could potentially indicate shifts in investor holdings or market sentiments towards the company, although the identities of the buyer and seller remain undisclosed.